^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    1d
    Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    1d
    Validation of the Association Between the Abundance of Three Bacterial Genera in Stool Samples and the Risk of Gallbladder Cancer in South American Patients With Gallstones (clinicaltrials.gov)
    P=N/A, N=120, Completed, Centre Paul Strauss
    New trial
    2d
    Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer. (PubMed, Sci Rep)
    In the MSKCC cohort, high tumor mutational burden (TMB-Hmed) correlated with poorer OS (HR = 1.43, P = 0.01), while PBRM1 mutations were associated with improved survival (HR = 0.50, P = 0.02). This study underscores the distinct genomic profiles of GBC and CCA, offering valuable insights into the molecular underpinnings of these aggressive cancers and supporting the development of precision medicine strategies.
    Clinical data • Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • MCL1 (Myeloid cell leukemia 1) • PBRM1 (Polybromo 1) • ARID2 (AT-Rich Interaction Domain 2) • SOX2
    |
    TMB-H • ARID1A mutation
    5d
    Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=12, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    7d
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. (clinicaltrials.gov)
    P2, N=227, Not yet recruiting, GV20 Therapeutics
    New P2 trial
    7d
    CR-001-101: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors (2025-523590-42-00)
    P1/2, N=44, Not yet recruiting, Crescent Biopharma Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation
    7d
    SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
    P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    8d
    Supramolecular coordination nanoplatform amplifies oxidative stress to overcome ferroptosis resistance in gallbladder cancer. (PubMed, J Nanobiotechnology)
    ICFe@D demonstrated potent and consistent tumor regression across heterogeneous patient-specific models with minimal systemic toxicity. This study presents a highly translatable and precise nanotherapeutic strategy that effectively sensitizes GBC to ferroptosis, providing a valuable preclinical framework for biliary tract cancer therapy.
    Journal
    |
    HMOX1 (Heme Oxygenase 1) • GPX4 (Glutathione Peroxidase 4)
    9d
    Prognostic Significance of Her-2/Neu and Ki-67 Expression in Gallbladder Carcinoma: A Clinicopathological Study Across Resectable and Advanced Stages. (PubMed, Cureus)
    Conclusion Her-2/Neu positivity declines with poor tumor differentiation, without any effect on prognosis in resectable GBC. The Ki67 index, along with tumor grading, offers potential as a predictive and prognostic marker in resectable GBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    9d
    Plasma metabolomics identifies trimethylamine n-oxide as an accelerator of gallstone disease accompanied by early neoplastic alterations in mice. (PubMed, Am J Physiol Gastrointest Liver Physiol)
    TMAO is a key metabolite associated with GSD and CaGB. TMAO supplementation with lithogenic diet accelerated gallstone formation, accompanied by preneoplastic changes, and disrupted bile acid regulation.
    Preclinical • Journal • Metabolomic study
    |
    IL10 (Interleukin 10) • ABCC3 (ATP Binding Cassette Subfamily C Member 3)
    9d
    Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • guadecitabine (SGI-110)
    12d
    Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Shanghai Zhongshan Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV